xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.23262, Wiley Online Library on [02/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

366

KUANetal.

TABLE XXXII.4 Evidence surrounding QOL after chemotherapy and immunotherapy for SNM.

Clinical endpoints

Study

Year LOE Study design Study groups

Conclusion

Kimet al. 2171

1. Patients undergoing IC plus CRT had higher rates of grade 3/4 neutropenia, anemia, and thrombocytopenia 2. There was no difference in the rates of nonhematologic toxicities 3. Patients undergoing IC were less likely to complete CRT There was a 3.96 odds ratio of all-grade pneumonitis and a 2.87 odds ratio for high-grade pneumonitis following treatment with immune checkpoint inhibitors pembrolizumab group was hypothyroidism and in the standard group was fatigue pembrolizumab group suffered treatment-related death versus two patients in the standard of caregroup 1. The most common grade 3 + toxicity during IC was neutropenia 2. During CRT, there was significantly higher rates of neutropenia in the IC group, and higher rates of skin rash (likely due to cetuximab) in the CRT group 3. Receipt of IC did not affect compliance to CRT 1. 38% of patients experienced grade 3 + toxicity 2. Late esophageal toxicity was more frequent in the IV group 3. There were no other differences in toxicity rates between the IV and IA groups (Continues) 3. Four patients in the

1. Treatment toxicities 2. Treatment compliance

2016 1

Meta-analysis ofRCTs

Patients with locally advanced head and neck cancer treated with IC with TPF plusCRT( n = 651) or CRT alone ( n = 629) 6671 patients receiving immune checkpoint inhibitors versus standard chemotherapy,

Abdel-Rahman andFouad 2188

2016 1

Meta-analysis ofRCTs

Development of pneumonitis

placebo, or everolimus

Cohen et al. 2189

Incidence of AEs 1. There was a lower incidence of grade 3 + AEs in the pembrolizumab group than the standard therapy group 2. The most common AE in the

2019 2

RCT

Patients with recurrent,

progressive, or metastatic head and neck SCC failing platinum therapy, then receiving

pembrolizumab ( n = 247) versus standard

methotrexate, docetaxel, or cetuximab ( n = 248)

Ghi et al. 2165

2017 2

RCT

421 patients with

1. Treatment toxicities 2. Treatment compliance

locally advanced head and neck cancer receiving CRT( n = 208) versus IC TPF followed by CRT ( n = 206)

Heukelom et al. 2179

Severe late

2016 2

RCT

237 patients with

treatment toxicities

inoperable head and neck cancer treated with IA cisplatin plusRT( n = 118) versus IV cisplatin plusRT( n = 119)